The DOI matches its Crossref record; 67 of the 67 references it cites were found in a registry or an index.
Genomic variants, genes, and pathways of Alzheimer's disease: An overview
Open accessAbstract
Alzheimer's disease (AD) (MIM: 104300) is a highly heritable disease with great complexity in its genetic contributors, and represents the most common form of dementia. With the gradual aging of the world's population, leading to increased prevalence of AD, and the substantial cost of care for those afflicted, identifying the genetic causes of disease represents a critical effort in identifying therapeutic targets. Here we provide a comprehensive review of genomic studies of AD, from the earliest linkage studies identifying monogenic contributors to early‐onset forms of AD to the genome‐wide and rare variant association studies of recent years that are being used to characterize the mosaic of genetic contributors to late‐onset AD (LOAD), and which have identified approximately ∼20 genes with common variants contributing to LOAD risk. In addition, we explore studies employing alternative approaches to identify genetic contributors to AD, including studies of AD‐related phenotypes and multi‐variant association studies such as pathway analyses. Finally, we introduce studies of next‐generation sequencing, which have recently helped identify multiple low‐frequency and rare variant contributors to AD, and discuss on‐going efforts with next‐generation sequencing studies to develop statistically well‐ powered and comprehensive genomic studies of AD. Through this review, we help uncover the many insights the genetics of AD have provided into the pathways and pathophysiology of AD. © 2016 Wiley Periodicals, Inc.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Corder, E. H., Saunders, A. M., Strittmatter, W. J., Schmechel, D. E., Gaskell, P. C., Small, G. W., Roses, A. D., Haines, J. L., & Pericak-Vance, M. A. (1993) · Science · doi:10.1126/science.8346443 · Cited by 9,429
Goate, A., Chartier-Harlin, M.-C., Mullan, M., Brown, J., Crawford, F., Fidani, L., Giuffra, L., Haynes, A., Irving, N., James, L., et al. (1991) · Nature · doi:10.1038/349704a0 · Cited by 4,659
A second generation human haplotype map of over 3.1 million SNPs
The International HapMap Consortium (2007) · Nature · doi:10.1038/nature06258 · Cited by 4,438
Meta-Analysis of 74,046 Individuals Identifies 11 New Susceptibility Loci for Alzheimer’s Disease
(EADI), E. A. D. I., Lambert, J.-C., (GERAD), G. A. E. R. I. A. D., Alzheimer's Disease Genetic Consortium (ADGC), (CHARGE), C. F. H. A. A. R. I. G. E., Ibrahim-Verbaas, C. A., Harold, D., Naj, A. C., Sims, R., Bellenguez, C., et al. (2013) · Nature Genetics · doi:10.1038/ng.2802 · Cited by 4,336 · cited 2×
“…37,154 controls of European ancestry, with de novo genotyping of variants with genome-wide significant and suggestive associations (P 0.001) in a large replication dataset of 8,572 AD cases and 11,312 cognitive controls frommultiple European datasets without available GWAS [Lambert et al., 2013b].”
BackgroundMethodInfluentialSelf-citationBlessed, G., Tomlinson, B. E., & Roth, M. (1968) · British Journal of Psychiatry · doi:10.1192/bjp.114.512.797 · Cited by 4,117 · cited 2×
“At that time, AD was thought to be a rare cause of senility, a notion thatwas refuted in the 1960s with an autopsy series by Blessed, Tomlinson, and Roth performed on hundreds of brains affected with “normal senility,” which revealed that the majority were affected by the plaque and tangle lesions characteristic of AD…”
ResultCloning of a gene bearing missense mutations in early-onset familial Alzheimer's disease
Sherrington, R., Rogaev, E. I., Liang, Y., Rogaeva, E. A., Levesque, G., Ikeda, M., Chi, H., Lin, C., Li, G., Holman, K., et al. (1995) · Nature · doi:10.1038/375754a0 · Cited by 4,051
Apolipoprotein E: Cholesterol Transport Protein with Expanding Role in Cell Biology
Mahley, R. W. (1988) · Science · doi:10.1126/science.3283935 · Cited by 4,028 · cited 1×
“2) [Olaisen et al., 1982;Das et al., 1985], APOE encodes apolipoprotein E (ApoE), a serum protein synthe- sized by astrocytes [Mahley, 1988] involved in the transport, storage, and metabolism of lipid.”
BackgroundAssociation of apolipoprotein E allele ϵ4 with late‐onset familial and sporadic Alzheimer's disease
Saunders, A. M., Strittmatter, W. J., Schmechel, D., St. George-Hyslop, P. H., Pericak-Vance, M. A., Joo, S. H., Rosi, B. L., Gusella, J. F., Crapper-MacLachlan, D. R., Alberts, M. J., et al. (1993) · Neurology · doi:10.1212/wnl.43.8.1467 · Cited by 3,786
Harold, D., Abraham, R., Hollingworth, P., Sims, R., Gerrish, A., Hamshere, M. L., Pahwa, J. S., Moskvina, V., Dowzell, K., Williams, A., et al. (2009) · Nature Genetics · doi:10.1038/ng.440 · Cited by 3,326
TREM2 Variants in Alzheimer's Disease
Guerreiro, R., Wojtas, A., Bras, J., Carrasquillo, M., Rogaeva, E., Majounie, E., Cruchaga, C., Sassi, C., Kauwe, J. S. K., Younkin, S., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1211851 · Cited by 3,020
Alzheimer disease in the United States (2010–2050) estimated using the 2010 census
Hebert, L. E., Weuve, J., Scherr, P. A., & Evans, D. A. (2013) · Neurology · doi:10.1212/wnl.0b013e31828726f5 · Cited by 2,642
Candidate gene for the chromosome 1 familial Alzheimer’s disease locus
Levy-Lahad, E., Wasco, W., Poorkaj, P., Romano, D. M., Oshima, J., Pettingell, W. H., Yu, C.-E., Jondro, P. D., Schmidt, S. D., Wang, K., et al. (1995) · Science · doi:10.1126/science.7638622 · Cited by 2,577
Self-citationVariant of TREM2 Associated with the Risk of Alzheimer's Disease
Jonsson, T., Stefansson, H., Steinberg, S., Jonsdottir, I., Jonsson, P. V., Snaedal, J., Bjornsson, S., Huttenlocher, J., Levey, A. I., Lah, J. J., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1211103 · Cited by 2,558 · cited 1×
“1 geneTREM2 have recently been found to lead to an increase of as much as 400% in AD risk [Guerreiro et al., 2012, 2013a,b; Jonsson et al., 2013].”
BackgroundAlzheimer Disease in the US Population: Prevalence Estimates Using the 2000 Census
Hebert, L. E., Scherr, P. A., Bienias, J. L., Bennett, D. A., & Evans, D. A. (2003) · Archives of Neurology · doi:10.1001/archneur.60.8.1119 · Cited by 2,168 · cited 1×
“As the population continues to age, the prevalence is expected to increase almost threefold by 2050 [Hebert et al., 2003], making AD not only a common, but also a growing health crisis.”
BackgroundRogaev, E. I., Sherrington, R., Rogaeva, E. A., Levesque, G., Ikeda, M., Liang, Y., Chi, H., Lin, C., Holman, K., Tsuda, T., et al. (1995) · Nature · doi:10.1038/376775a0 · Cited by 2,052 · cited 4×
“…<60 years): APP, encoding amyloid precursor protein [Goate et al., 1991], and PS1 and PS2, encoding presenilins I and II respectively [Levy-Lahad et al., 1995; Rogaev et al., 1995; Sherrington et al., 1995], each transmitting disease-causing var- iants in the predicted autosomal-dominant fashion.”
BackgroundInfluentialInitiative, T. A. D. N., Hollingworth, P., CHARGE consortium, EADI1 consortium, Harold, D., Sims, R., Gerrish, A., Lambert, J.-C., Carrasquillo, M. M., Abraham, R., et al. (2011) · Nature Genetics · doi:10.1038/ng.803 · Cited by 1,997 · cited 4×
“To maximize sample size and thereby power to detect LOAD susceptibility loci with even more modest effects, the four consor- tia, ADGC, EADI, GERAD, and CHARGE, combined data and analytical resources to form a mega-consortium, the International Genomics of Alzheimer’s Project (IGAP), to conduct a newGWAS.”
ResultInfluentialMixed brain pathologies account for most dementia cases in community-dwelling older persons
Schneider, J. A., Arvanitakis, Z., Bang, W., & Bennett, D. A. (2007) · Neurology · doi:10.1212/01.wnl.0000271090.28148.24 · Cited by 1,992
Protective effect of apolipoprotein E type 2 allele for late onset Alzheimer disease
Corder, E. H., Saunders, A. M., Risch, N. J., Strittmatter, W. J., Schmechel, D. E., Gaskell, P. C., Rimmler, J. B., Locke, P. A., Conneally, P. M., Schmader, K. E., et al. (1994) · Nature Genetics · doi:10.1038/ng0694-180 · Cited by 1,920
Naj, A. C., Jun, G., Beecham, G. W., Wang, L.-S., Vardarajan, B. N., Buros, J., Gallins, P. J., Buxbaum, J. D., Jarvik, G. P., Crane, P. K., et al. (2011) · Nature Genetics · doi:10.1038/ng.801 · Cited by 1,901
Self-citationSystematic meta-analyses of Alzheimer disease genetic association studies: the AlzGene database
Bertram, L., McQueen, M. B., Mullin, K., Blacker, D., & Tanzi, R. E. (2007) · Nature Genetics · doi:10.1038/ng1934 · Cited by 1,857 · cited 1×
“Hun- dreds of genes have been individually tested for association with LOAD, and associations have been reported for nearly 150 genes, but few have replicated and none have gained wide acceptance (AlzGene database (http://www.alzgene.org/) accessed March 1, 2016 [Bertram et al., 2007]).”
BackgroundRole of Genes and Environments for Explaining Alzheimer Disease
Gatz, M., Reynolds, C. A., Fratiglioni, L., Johansson, B., Mortimer, J. A., Berg, S., Fiske, A., & Pedersen, N. L. (2006) · Archives of General Psychiatry · doi:10.1001/archpsyc.63.2.168 · Cited by 1,798
A mutation in APP protects against Alzheimer’s disease and age-related cognitive decline
Jonsson, T., Atwal, J. K., Steinberg, S., Snaedal, J., Jonsson, P. V., Bjornsson, S., Stefansson, H., Sulem, P., Gudbjartsson, D., Maloney, J., et al. (2012) · Nature · doi:10.1038/nature11283 · Cited by 1,738
The support of human genetic evidence for approved drug indications
Nelson, M. R., Tipney, H., Painter, J. L., Shen, J., Nicoletti, P., Shen, Y., Floratos, A., Sham, P. C., Li, M. J., Wang, J., et al. (2015) · Nature Genetics · doi:10.1038/ng.3314 · Cited by 1,666
Integrated Systems Approach Identifies Genetic Nodes and Networks in Late-Onset Alzheimer’s Disease
Zhang, B., Gaiteri, C., Bodea, L.-G., Wang, Z., McElwee, J., Podtelezhnikov, A. A., Zhang, C., Xie, T., Tran, L., Dobrin, R., et al. (2013) · Cell · doi:10.1016/j.cell.2013.03.030 · Cited by 1,657
Gene-Wide Analysis Detects Two New Susceptibility Genes for Alzheimer's Disease
Escott-Price, V., Bellenguez, C., Wang, L.-S., Choi, S.-H., Harold, D., Jones, L., Holmans, P., Gerrish, A., Vedernikov, A., Richards, A., et al. (2014) · PLoS ONE · doi:10.1371/journal.pone.0094661 · Cited by 1,398
Self-citationStrittmatter, W. J., Weisgraber, K. H., Huang, D. Y., Dong, L. M., Salvesen, G. S., Pericak-Vance, M., Schmechel, D., Saunders, A. M., Goldgaber, D., & Roses, A. D. (1993) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.90.17.8098 · Cited by 1,363 · cited 1×
“…gene for LOAD, the Apolipopro- tein E (APOE) gene, was initially discovered using linkage analysis [Pericak-Vance et al., 1991] in a subset of AD affected individuals with an age-at-onset (AAO) greater than or equal to 60 years of age, followed by association analysis [Strittmatter et al., 1993].”
MethodEvans, D. A. (1989) · JAMA · doi:10.1001/jama.1989.03430180093036 · Cited by 1,226 · cited 1×
“…also increases with age, from 0.3–0.5% at age 60, to 11–15% at age 80 [Rocca et al., 1991; Bachman et al., 1992; Prencipe et al., 1996], although there is considerable vari- ability in these rate estimates, with some reports finding prevalence as high as 47% after age 84 [Evans et al., 1989].”
ResultInfluentialThe neuronal sortilin-related receptor SORL1 is genetically associated with Alzheimer disease
Rogaeva, E., Meng, Y., Lee, J. H., Gu, Y., Kawarai, T., Zou, F., Katayama, T., Baldwin, C. T., Cheng, R., Hasegawa, H., et al. (2007) · Nature Genetics · doi:10.1038/ng1943 · Cited by 1,167
Apolipoprotein E in sporadic Alzheimer's disease: Allelic variation and receptor interactions
William Rebeck, G., Reiter, J. S., Strickland, D. K., & Hyman, B. T. (1993) · Neuron · doi:10.1016/0896-6273(93)90070-8 · Cited by 1,107
Tang, M.-X. (1998) · JAMA · doi:10.1001/jama.279.10.751 · Cited by 771
Human apolipoprotein E. The complete amino acid sequence
Rall, S. C., Weisgraber, K. H., & Mahley, R. W. (1982) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(18)34702-1 · Cited by 741
A Highly Conserved Program of Neuronal Microexons Is Misregulated in Autistic Brains
Irimia, M., Weatheritt, R. J., Ellis, J. D., Parikshak, N. N., Gonatopoulos-Pournatzis, T., Babor, M., Quesnel-Vallières, M., Tapial, J., Raj, B., O’Hanlon, D., et al. (2014) · Cell · doi:10.1016/j.cell.2014.11.035 · Cited by 693 · cited 2×
“CYP1A1 encodes aromatase, which is involved in estrogen regulation, while SRRM4 regulates alternative splicing of microexons in the brain, and misregulation of which has been linked to autism spectrum dis- orders [Irimia et al., 2014].”
BackgroundPaloneva, J., Manninen, T., Christman, G., Hovanes, K., Mandelin, J., Adolfsson, R., Bianchin, M., Bird, T., Miranda, R., Salmaggi, A., et al. (2002) · The American Journal of Human Genetics · doi:10.1086/342259 · Cited by 683
Weisgraber, K. H., Innerarity, T. L., & Mahley, R. W. (1982) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(18)34954-8 · Cited by 673
Molecular genetics of early-onset Alzheimer’s disease revisited
Cacace, R., Sleegers, K., & Van Broeckhoven, C. (2016) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2016.01.012 · Cited by 617
Jones, L., Holmans, P. A., Hamshere, M. L., Harold, D., Moskvina, V., Ivanov, D., Pocklington, A., Abraham, R., Hollingworth, P., Sims, R., et al. (2010) · PLoS ONE · doi:10.1371/journal.pone.0013950 · Cited by 606
Lemere, C. A., Blusztajn, J. K., Yamaguchi, H., Wisniewski, T., Saido, T. C., & Selkoe, D. J. (1996) · Neurobiology of Disease · doi:10.1006/nbdi.1996.0003 · Cited by 584 · cited 2×
“In 1995, AD-causing mutations were identified in PSEN1 [Sherrington et al., 1995], which contributed to an aggressive form of AD [Selkoe, 2001] with relative abundance of Ab42 accumulation [Lemere et al., 1996; Mann et al., 1996].”
BackgroundCoon, K. D., Myers, A. J., Craig, D. W., Webster, J. A., Pearson, J. V., Lince, D. H., Zismann, V. L., Beach, T. G., Leung, D., Bryden, L., et al. (2007) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v68n0419 · Cited by 569
Bertram, L., Lange, C., Mullin, K., Parkinson, M., Hsiao, M., Hogan, M. F., Schjeide, B. M. M., Hooli, B., DiVito, J., Ionita, I., et al. (2008) · The American Journal of Human Genetics · doi:10.1016/j.ajhg.2008.10.008 · Cited by 511
The endophenotype concept in psychiatric genetics
FLINT, J., & MUNAFÒ, M. R. (2007) · Psychological Medicine · doi:10.1017/s0033291706008750 · Cited by 477
Rare coding variants in the phospholipase D3 gene confer risk for Alzheimer’s disease
Cruchaga, C., Karch, C. M., Jin, S. C., Benitez, B. A., Cai, Y., Guerreiro, R., Harari, O., Norton, J., Budde, J., Bertelsen, S., et al. (2014) · Nature · doi:10.1038/nature12825 · Cited by 461
Reitz, C., Jun, G., Naj, A., Rajbhandary, R., Vardarajan, B. N., Wang, L.-S., Valladares, O., Lin, C.-F., Larson, E. B., Graff-Radford, N. R., et al. (2013) · JAMA · doi:10.1001/jama.2013.2973 · Cited by 431
Self-citationGWAS of Cerebrospinal Fluid Tau Levels Identifies Risk Variants for Alzheimer’s Disease
Cruchaga, C., Kauwe, J. S. K., Harari, O., Jin, S. C., Cai, Y., Karch, C. M., Benitez, B. A., Jeng, A. T., Skorupa, T., Carrell, D., et al. (2013) · Neuron · doi:10.1016/j.neuron.2013.02.026 · Cited by 383
Self-citationPotkin, S. G., Guffanti, G., Lakatos, A., Turner, J. A., Kruggel, F., Fallon, J. H., Saykin, A. J., Orro, A., Lupoli, S., Salvi, E., et al. (2009) · PLoS ONE · doi:10.1371/journal.pone.0006501 · Cited by 376
Evans, D. A., Bennett, D. A., Wilson, R. S., Bienias, J. L., Morris, M. C., Scherr, P. A., Hebert, L. E., Aggarwal, N., Beckett, L. A., Joglekar, R., et al. (2003) · Archives of Neurology · doi:10.1001/archneur.60.2.185 · Cited by 370
Age at Onset in Two Common Neurodegenerative Diseases Is Genetically Controlled
Li, Y.-J., Scott, W. K., Hedges, D. J., Zhang, F., Gaskell, P. C., Nance, M. A., Watts, R. L., Hubble, J. P., Koller, W. C., Pahwa, R., et al. (2002) · The American Journal of Human Genetics · doi:10.1086/339815 · Cited by 312
Genetic variation in PCDH11X is associated with susceptibility to late-onset Alzheimer’s disease
Carrasquillo, M. M., Zou, F., Pankratz, V. S., Wilcox, S. L., Ma, L., Walker, L. P., Younkin, S. G., Younkin, C. S., Younkin, L. H., Bisceglio, G. D., et al. (2009) · Nature Genetics · doi:10.1038/ng.305 · Cited by 296
Genome-wide Association Study Implicates a Chromosome 12 Risk Locus for Late-Onset Alzheimer Disease
Beecham, G. W., Martin, E. R., Li, Y.-J., Slifer, M. A., Gilbert, J. R., Haines, J. L., & Pericak-Vance, M. A. (2009) · The American Journal of Human Genetics · doi:10.1016/j.ajhg.2008.12.008 · Cited by 260
Corneveaux, J. J., Myers, A. J., Allen, A. N., Pruzin, J. J., Ramirez, M., Engel, A., Nalls, M. A., Chen, K., Lee, W., Chewning, K., et al. (2010) · Human Molecular Genetics · doi:10.1093/hmg/ddq221 · Cited by 237
Genetic Variation and Neuroimaging Measures in Alzheimer Disease
Biffi, A. (2010) · Archives of Neurology · doi:10.1001/archneurol.2010.108 · Cited by 222
Replication of CLU, CR1, and PICALM Associations With Alzheimer Disease
Carrasquillo, M. M., Belbin, O., Hunter, T. A., Ma, L., Bisceglio, G. D., Zou, F., Crook, J. E., Pankratz, V. S., Dickson, D. W., Graff-Radford, N. R., et al. (2010) · Archives of Neurology · doi:10.1001/archneurol.2010.147 · Cited by 208
Miyashita, A., Koike, A., Jun, G., Wang, L.-S., Takahashi, S., Matsubara, E., Kawarabayashi, T., Shoji, M., Tomita, N., Arai, H., et al. (2013) · PLoS ONE · doi:10.1371/journal.pone.0058618 · Cited by 196
Self-citationA genome-wide association study for late-onset Alzheimer's disease using DNA pooling
Abraham, R., Moskvina, V., Sims, R., Hollingworth, P., Morgan, A., Georgieva, L., Dowzell, K., Cichon, S., Hillmer, A. M., O'Donovan, M. C., et al. (2008) · BMC Medical Genomics · doi:10.1186/1755-8794-1-44 · Cited by 195
Naj, A. C., Jun, G., Reitz, C., Kunkle, B. W., Perry, W., Park, Y. S., Beecham, G. W., Rajbhandary, R. A., Hamilton-Nelson, K. L., Wang, L.-S., et al. (2014) · JAMA Neurology · doi:10.1001/jamaneurol.2014.1491 · Cited by 185
Self-citationMann, D. M. A., Iwatsubo, T., Cairns, N. J., Lantos, P. L., Nochlin, D., Sumi, S. M., Bird, T. D., Poorkaj, P., Hardy, J., Hutton, M., et al. (1996) · Annals of Neurology · doi:10.1002/ana.410400205 · Cited by 184
Porter, V. R., Buxton, W. G., Fairbanks, L. A., Strickland, T., O'Connor, S. M., Rosenberg-Thompson, S., & Cummings, J. L. (2003) · The Journal of Neuropsychiatry and Clinical Neurosciences · doi:10.1176/jnp.15.2.180 · Cited by 182 · cited 2×
“[Teri et al., 1999; Porter et al., 2003], and psychosis (41.1”
InfluentialA Genomewide Screen for Late-Onset Alzheimer Disease in a Genetically Isolated Dutch Population
Liu, F., Arias-Vásquez, A., Sleegers, K., Aulchenko, Y. S., Kayser, M., Sanchez-Juan, P., Feng, B.-J., Bertoli-Avella, A. M., van Swieten, J., Axenovich, T. I., et al. (2007) · The American Journal of Human Genetics · doi:10.1086/518720 · Cited by 156
Accelerated decline in apolipoprotein E-ϵ4 homozygotes with Alzheimer's disease
Craft, S., Teri, L., Edland, S. D., Kukull, W. A., Schellenberg, G., McCormick, W. C., Bowen, J. D., & Larson, E. B. (1998) · Neurology · doi:10.1212/wnl.51.1.149 · Cited by 152 · cited 1×
“…appears to influence AD risk and AAO, it is unclear if it affects ADprogression, with studies indicating itmay accelerate [Lehtovirta et al., 1996; Craft et al., 1998; Dik et al., 2000; Deary et al., 2002], slow [Frisoni et al., 1995; Stern et al., 1997], or have no effect on disease progression…”
BackgroundSelf-citationGenetics of Alzheimer's disease: recent advances
Avramopoulos, D. (2009) · Genome Medicine · doi:10.1186/gm34 · Cited by 136
EADI consortium, G. C., Lambert, J.-C., Grenier-Boley, B., Harold, D., Zelenika, D., Chouraki, V, Kamatani, Y., Sleegers, K., Ikram, M. A., Hiltunen, M., et al. (2013) · Molecular Psychiatry · doi:10.1038/mp.2012.14 · Cited by 129
Farrer, L. A. (1997) · JAMA · doi:10.1001/jama.1997.03550160069041 · Cited by 124
Association of Apolipoprotein E Genotype and Alzheimer Disease in African Americans
Murrell, J. R., Price, B., Lane, K. A., Baiyewu, O., Gureje, O., Ogunniyi, A., Unverzagt, F. W., Smith-Gamble, V., Gao, S., Hendrie, H. C., et al. (2006) · Archives of Neurology · doi:10.1001/archneur.63.3.431 · Cited by 108
Guerreiro, R. J., Lohmann, E., Kinsella, E., Brás, J. M., Luu, N., Gurunlian, N., Dursun, B., Bilgic, B., Santana, I., Hanagasi, H., et al. (2012) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2011.10.009 · Cited by 107 · cited 2×
“1 geneTREM2 have recently been found to lead to an increase of as much as 400% in AD risk [Guerreiro et al., 2012, 2013a,b; Jonsson et al., 2013].”
BackgroundGenome-wide association analysis of age-at-onset in Alzheimer's disease
Kamboh, M. I., Barmada, M. M., Demirci, F. Y., Minster, R. L., Carrasquillo, M. M., Pankratz, V. S., Younkin, S. G., Saykin, A. J., Initiative, T. A. D. N., Sweet, R. A., et al. (2012) · Molecular Psychiatry · doi:10.1038/mp.2011.135 · Cited by 100 · cited 2×
“Finally, a study from the University of Pittsburgh [Kamboh et al., 2012b] with 1,291 cases and 938 controls examin- ing 2.5 million imputed SNPs observed its most significant novel association in the chromosome 15q21.”
BackgroundResultInfluentialHan, M.-R., Schellenberg, G. D., Wang, L.-S., & Initiative, T. A. D. N. (2010) · BMC Neurology · doi:10.1186/1471-2377-10-90 · Cited by 93
Self-citationMartiskainen, H., Viswanathan, J., Nykänen, N.-P., Kurki, M., Helisalmi, S., Natunen, T., Sarajärvi, T., Kurkinen, K. M. A., Pursiheimo, J.-P., Rauramaa, T., et al. (2015) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2014.09.003 · Cited by 70
Kunkle, B. W., Jaworski, J., Barral, S., Vardarajan, B., Beecham, G. W., Martin, E. R., Cantwell, L. S., Partch, A., Bird, T. D., Raskind, W. H., et al. (2016) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2015.05.020 · Cited by 32 · cited 1×
“…the sample sets being incorporated into the ADSP includes whole genome linkage analyses using GWAS data on multiplex White and Caribbean Hispanic pedigrees to identify candidate genomic regions for particular focus in an upcoming genome scan of WGS data [Barral et al., 2015; Kunkle et al., 2016].”
MethodSelf-citation
Cited by
Scheltens, P., De Strooper, B., Kivipelto, M., Holstege, H., Chételat, G., Teunissen, C. E., Cummings, J., & van der Flier, W. M. (2021) · The Lancet · doi:10.1016/s0140-6736(20)32205-4 · Cited by 5,465
APP mouse models for Alzheimer’s disease preclinical studies.
Sasaguri, H., Nilsson, P., Hashimoto, S., Nagata, K., Saito, T., De Strooper, B., Hardy, J., Vassar, R., Winblad, B., & Saido, T. C. (2017) · The EMBO Journal · doi:10.15252/embj.201797397 · Cited by 793
Blood-based biomarkers for Alzheimer disease: mapping the road to the clinic
Hampel, H., O’Bryant, S. E., Molinuevo, J. L., Zetterberg, H., Masters, C. L., Lista, S., Kiddle, S. J., Batrla, R., & Blennow, K. (2018) · Nature Reviews Neurology · doi:10.1038/s41582-018-0079-7 · Cited by 716
Current state of Alzheimer’s fluid biomarkers
Molinuevo, J. L., Ayton, S., Batrla, R., Bednar, M. M., Bittner, T., Cummings, J., Fagan, A. M., Hampel, H., Mielke, M. M., Mikulskis, A., et al. (2018) · Acta Neuropathologica · doi:10.1007/s00401-018-1932-x · Cited by 518
ApoE4: an emerging therapeutic target for Alzheimer’s disease
Safieh, M., Korczyn, A. D., & Michaelson, D. M. (2019) · BMC Medicine · doi:10.1186/s12916-019-1299-4 · Cited by 449
Metadata
- Authors
- Naj, A. C., Schellenberg, G. D., & for the Alzheimer's Disease Genetics Consortium (ADGC)
- Venue
- American Journal of Medical Genetics Part B: Neuropsychiatric Genetics
- Publisher
- Wiley
- Published
- 2016-12-12
- Volume
- 174
- Issue
- 1
- Pages
- 5-26
- ISSN
- 1552-4841 (ISSN-L)
- 1552-485X
- OpenAlex
- W2564710687
- Cited by
- 179
- References
- 67
- FWCI
- 13.46
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.